Radiotraceurs de tomographie par émission de positrons (TEP) de fluoro-oxystérols

Le résumé fourni par la source

Radiopharmaceuticals-based biomedical imaging plays a growing role in cancer management, including diagnosis, tumor staging and aggressiveness and treatment monitoring. Even though 18Fluoro-2-deoxy glucose and 18Fluoroestradiol are currently used for some types of breast cancer, a need remains to develop other candidate compounds which are useful as radiotracers in a different/ broader range of cancer types. Thus, it is described a family of 18F radiolabeled compounds of formula (I) (wherein one of R2, R4, R5, R6, R7 and R12 is 18F) for use as Positron Emission Tomography imaging agents for the detection of cancers and metastatic sites thereof, as well as for monitoring and predicting the efficacy of a cancer treatment, wherein the cancer is associated to cholesterol-5,6- epoxide hydrolase and/or lip-hydroxy steroid dehydrogenase type (2) overexpression. To overcome the issues linked to the lifetime of the radioisotope 18F and, to ensure an effective synthesis of the 18F radiolabeled compounds of formula (I), a group of novel intermediate compounds in the synthesis thereof is also described.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.